Drug intelligence / Profile preview

A51R3

Development stage: Unknown
Lead developer: AJU Pharm
Modality: Small Molecules
Administration: Oral

Overview

A51R3 is an investigational drug used in clinical trials for the treatment of type 2 diabetes mellitus. It is being studied as part of combination therapy regimens, particularly in combination with AJU-A51 and A51R2, to improve glycemic control in patients who have inadequate response to other therapies. The specific mechanism of action, molecular target(s), and chemical structure of A51R3 are not publicly disclosed as of June 2025. Clinical studies indicate its use within a regimen designed to optimize blood glucose levels in type 2 diabetes patients[2][4][5].

Beyond the preview

Go deeper on A51R3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A51R3.

Explore the full profile